Accreditation is designed to preserve the safety and integrity of the pharmaceutical supply chain
Woburn, Mass., June 23, 2009 – CutisPharma, Inc. announced today that it has received Verified Accredited Wholesale Distributors (VAWD) accreditation from the National Association of Boards of Pharmacy (NABP) for its Woburn, Massachusetts facility. In March 2007 the company received accreditation for its Beverly facility. The NABP developed VAWD in response to the Food and Drug Administration’s (FDA) Counterfeit Drug Task Force findings and recommendations. Applicants undergo a thorough criteria compliance review, licensure verification, employee background checks, screening through the NABP Clearinghouse and a comprehensive on-site inspection conducted by NABP experts.
CutisPharma is a specialty pharmaceutical company that develops and commercializes FI℞ST® Unit-of-Use Prescription Compounding Kits. The Company distributes its own private label products to National Wholesalers, Regional Distributors and Chain Drug stores. “We are pleased to receive our second VAWD accreditation from the National Association of the Boards of Pharmacy” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “Our participation in the accreditation program further demonstrates our commitment towards providing quality prescription pharmaceutical products to our customers.”
CutisPharma currently has nine proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and one Magic Mouthwash kit. The Company plans on introducing three new prescription mouthwash products this fall, and several more compounding kits are in the planning stages. FI℞ST® Unit-of-Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter <795>.
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FI℞ST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.
V.P. Business Development
CutisPharma, Inc. 978-867-1010 x20
For more information please visit our website at www.cutispharma.com
NABP is the independent, international, and impartial Association that assists its member boards and jurisdictions in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health.
For more information about NABP or NABP’s VAWD program, visit NABP’s website at http://www.nabp.net